Dive Brief: Roche has outlined a new clinical path forward for a closely watched Huntington’s disease drug ten months after disappointing Phase 3 study results …

Voyager’s first generation of gene therapies for ALS, Parkinson’s and Huntington’s disease, all now discontinued, relied on a direct infusion into brain tissue, an invasive …